KRRO Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.08%, SMA50 19.31%, SMA200 -36.05%). The stock’s 14-day RSI is 56.18 (neutral), while the ATR of 0.98 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.35% below its high and over 132.5% above its low. Average 10-day trading volume of 364.22 thousand shares is significantly above the 3-month average of 184.50 thousand, indicating heightened recent market interest.

Korro Bio, Inc. has 14.42 million shares outstanding. The public float is 9.53 million shares, elevated short interest at 11.36% of float. This equals 1.46 million shares. The short ratio is 4.86 days. Institutional investors hold 97.97% of the float. Insiders own 1.0%. Lynx1 Capital Management LP holds 1.54 million shares, Chang Carmen has 242.94 thousand shares and Yang Rick has 242.94 thousand shares. Over the past six months, insider transactions show net selling. They sold 100.34 thousand shares across 20 transactions.

Korro Bio, Inc. generated EPS of -$9.42 over the past year. Five-year average earnings growth is 21.83%. Wall Street analysts project EPS growth of 6.31% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 7 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $93.00 to $7.00. The high target offers 799.42% upside. The low target suggests -32.3% downside. The mean target is $23.57. This offers 127.95% upside. Korro Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -20.15%. The prior quarter beat by -2.12%. Over the last six quarters, Apple has recorded several small beats. These include -4.23% in May 07, 2025.

Korro Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.57. This means the shares are trading below this model’s fair value.

Korro Bio, Inc. (NASDAQ:KRRO) closed at $10.34 USD, gaining $0.36 (3.61%) from the previous close of $9.98. The stock is currently mid-range between its 52-week high and low $5.20 and $55.89. With a market capitalization of about $102.92 million, Korro Bio, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.25). Key stats such as the average daily volume over the past year has been around 181.53 thousand shares, in line with its 52-week average. Headquartered in Cambridge, MA, Korro Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ram Aiyar, the company employs approximately 57 people and listed since October 03, 2019. Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics.

Korro Bio, Inc. trades at a P/E ratio of -1.04, slightly below the S&P 500 average, with a price-to-sales ratio of 43.67 and a price-to-book ratio of 1.78 suggesting the stock is closer to book value. The P/FCF stands at -1.52, also above market averages.

Our AI price prediction model suggests that Korro Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.6%, with price expected at $10.14 by October 05, 2026, within a range of $9.14 to $11.10 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by December 18, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected gain of 147.39%, with price at $24.69 by September 21, 2027, within a range of $0.92 to $47.43.

Korro Bio, Inc. (NASDAQ:KRRO) shares are flat 7.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Korro Bio, Inc. trading at a premium to the broader market with a P/E of -1.04. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $57.85, suggesting 479.66% upside. Our AI forecast model points to short-term strength (1.6% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (147.39% over one year), with expected trading ranges indicating moderate volatility.